Easton Pharmaceuticals Provides Update on Initiatives Towards Its Cancer Drug "Xilive" & Its Mexican Government Regulatory Fi...
December 11 2013 - 11:55AM
Marketwired
Easton Pharmaceuticals Provides Update on Initiatives Towards Its
Cancer Drug "Xilive" and Its Mexican Government Regulatory Filing
Submission for "Viorra"
TORONTO, ON--(Marketwired - Dec 11, 2013) - Easton
Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company
that owns, designs, develops, and markets an array of
topically-delivered drugs and therapeutic healthcare products
provides update towards its 2 main initiatives, its minority
ownership interest for its early stage cancer drug "Xilive" and on
its Mexican government regulatory filing For Its "Viorra"
product.
The Company is attempting to allocate its financial resources in
the most cost effective manner possible. As a result of the
company's recent purchase of its minority ownership interest in its
early stage Cancer Drug "Xilive" and the positive feedback
received, Easton Pharmaceuticals has shifted its main focus towards
"Xilive" and initiating some form of early stage clinical trial
testing program as well as continuing with its government approval
process for "Viorra" in Mexico and other Latin American countries.
Easton Pharmaceuticals has initiated discussions with both in-house
consultants as well as third parties who have prior knowledge and
experience with bringing such a testing program forward with both
the FDA and within other countries such as Mexico and Canada. Due
to cost and regulatory reasons, the Company and the current
majority owners of its cancer drug "Xilive" believe the best course
of action for "Xilive" is to attempt to initially enter into some
form of testing protocol outside of the United States prior to
entering into more expensive FDA recognized clinical trials in the
United States. The Company believes its best to initially focus
towards other jurisdictions such as Mexico, Canada, Italy, Germany
and various other countries including China where costs are deemed
greatly reduced and regulations are considered quicker, much less
stringent and more favorable towards allowing the use of early
stage cancer drugs such as "Xilive" to be utilized on prospective
Cancer patients in controlled trials. Although certain states in
the United States allow for the use of experimental cancer Drugs on
compassionate grounds, such drugs would still fall under the
regulations of the Food and Drug Administration which will require
some type of approval process prior to being used on any
prospective patients. Countries such as Canada and certain
Provinces such as B.C. have less regulated processes and allow for
the use of early stage drugs to be used under certain exemptions
and circumstances. However, various countries such as Mexico and
other European countries, namely Germany and Italy are considered
the most open towards allowing the use of early stage experimental
cancer drugs such as "Xilive" and other treatments. The company is
presently attempting to develop relationships with certain cancer
clinics and physicians as well as patients from North America who
currently travel to these countries for treatments. It is estimated
that each year many thousands of individuals suffering from cancer
travel to these countries for treatments, which are not available
in the United States.
In other initiatives, through its consultants in Mexico, Easton
Pharmaceuticals believes it is close to sourcing out a
manufacturing and distribution partners in Mexico for its "Viorra"
product. Such manufacturing partners are considered FDA certified
facilities as well as being more cost effective than if it was
manufactured in the United States or Canada. BMV, the companies
consultants in Mexico who are presently spearheading the regulatory
and filing process in Mexico strongly believes the company could
gain government approval within the first half of 2014 where sales
through a distributor being sourced out by BMV will commence
shortly thereafter. The companies updated website is expected to be
brought online shortly where certain products can initially be
purchased by consumers in North America. It is currently in the
process of manufacturing a large batch of its final version of
"Viorra."
About Easton Pharmaceuticals Inc.
Easton Pharmaceuticals is a specialty pharmaceutical company
that owns, designs, develops, and markets topically-delivered Drugs
and therapeutic healthcare products, focused on Cancer and other
health issues related to male and female sexual dysfunction, wound
healing, pain, motion sickness, scar and stretch marks, cellulite,
varicose veins and other conditions. The company's gel formulation
is thought to be an innovative and unique transdermal delivery
system. Easton Pharmaceuticals product "VIORRA,"
is an over-the-counter aid for the treatment to restore and improve
vaginal moisture and elasticity which is believed to have a
positive effect on women's sexual desire and arousal, FSAD (Female
Sexual Arousal Disorder) the world market for these female
conditions are in excess of $2 billion. VIORRA is a
topical, daily-use product classified by the FDA as containing
Generally Recognized as Safe ingredients.
For More Information Visit http://www.eastonpharma.com
& http://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(The "Act"). In particular, when used in the preceding of
discussion, the words "pleased," "plan," "confident that,"
"believe," "expect," "should", expect", "anticipate", "intent to"
and similar conditional expressions are intended to identify
forward-looking statements within the meaning of the Act and are
subject to the safe harbor created by the Act. Such statements are
subject to certain risks and uncertainties and actual results could
differ materially from those expressed in any of the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, market conditions, general acceptance of
the company's products and technologies, competitive factors, the
ability to successfully complete additional or adequate financing
and other risks and uncertainties as stated in the company's
financial reports and filings which all investors are advised to
view.
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Apr 2024 to May 2024
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From May 2023 to May 2024